Idiopathic hypereosinophilic syndrome

Search Trials
Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)
Status:
Completed
Last Changed:
Feb 21, 2020
First Changed:
Jul 19, 2016
Disease(s):
Hypereosinophilic Syndrome
Intervention(s):
Mepolizumab 300 mgPlacebo matching mepolizumabActive OCS capsules (5 mg prednisolone or prednisone)Placebo matching OCS capsules
A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622
Status:
Completed
Last Changed:
Jun 23, 2020
First Changed:
Oct 10, 2017
Disease(s):
Hypereosinophilic Syndrome
Intervention(s):
Mepolizumab
Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION
Status:
Terminated
Last Changed:
Aug 7, 2013
First Changed:
Jun 28, 2011
Disease(s):
Cholestasis, Progressive Familial Intrahepatic 3
Intervention(s):
Yttrium microsphere injection
Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome
Status:
Completed
Last Changed:
Jul 29, 2020
First Changed:
Dec 19, 2005
Disease(s):
Hypereosinophilic Syndromes
Intervention(s):
Mepolizumab

Connect. Empower. Inspire.